Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Biotechnology

Healthcare
$27.61 -1.93%

-$0.51 today

Market cap
$3.49B
Beta
1.52
P/E (TTM)
-1400.0
EPS (TTM)
-$0.02
52W Low $13.06High $31.77

Volume 0.84M

Average 1.61M

ARQT Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin grows in line with its trailing trend

Q2 FY2026 selling, general & admin of $82.14M rose 18.7% year over year, in line with the +19.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 10.9% from the prior quarter. Over 3 fiscal years it compounded at +31.0% a year.

Context

  • Selling, general & admin amounted to 73.0% of revenue in FY2025, down 43.7 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $4.24B (+1445.6%) for the fiscal year ending Dec 2026, a step up from the +19.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$82.14M+10.9% QoQ
Last fiscal yearDec 2025
$274.55M+19.7% YoY
LTMJun 2026
$297.6M+19.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.7%+1688.5%+1669.7 pp
1 year+19.7%+1445.6%+1425.9 pp
3-year CAGR+31.0%+189.8%+158.8 pp
5-year CAGR+101.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
274.55M USD
Year-over-year change
+19.7%
4-year CAGR
+45.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ARQT compares with its peers on the latest reported figures

  • ARQT's LTM Jun 2026 selling, general & admin of $297.6M is the 2nd highest of the 6 companies compared; the peer median is $22.58M.
  • Its year-over-year change of +19.2% is the 2nd highest of 4, against a peer median of +5.5%.
  • Selling, general & admin amounts to 64.1% of revenue for ARQT, versus a peer median of 226.4%.
ARQT Competitors Peer median
Selling, General & Admin for ARQT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.14T +9732467.6%-14.5%—
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$297.6M +19.2%+31.0%64.1%
EVMNEvommune, Inc.LTM Mar 2026$22.64M ——226.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M +5.5%-4.4%269.8%
TTRXTurn Therapeutics Inc.LTM Mar 2026$6.31M ———
SLGLSol-Gel Technologies Ltd.LTM Mar 2026$4.1M -20.8%-17.5%22.2%
Peer median (excluding ARQT) $22.58M+5.5%-14.5%226.4%

Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.69M59.61M196.54M376.07M
Cost of Revenue763K754K4.99M19.13M36.7M
Gross Profit(763K)2.93M54.62M177.41M339.38M
Gross Margin—79.5%91.6%90.3%90.2%
Research & Development145.56M182.44M110.58M76.42M77.05M
Selling, General & Admin60.97M122.12M185.15M229.39M274.55M
Operating Expenses205.77M304.56M295.72M305.81M351.6M
Depreciation & Amortization454K934K750K2.6M4.67M
EBITDA(205.9M)(294.87M)(228.57M)(109.63M)1.78M
EBITDA Margin—-7999.8%-383.5%-55.8%0.5%
Operating Income(206.53M)(301.63M)(241.1M)(128.4M)(12.23M)
Operating Margin—-8183.0%-404.5%-65.3%-3.3%
Interest Income173K0000
Interest Expense015.65M29.71M27.17M12.08M
Other Income / Expenses173K(9.83M)(17.93M)(11M)(2.74M)
Income Before Tax(206.36M)(311.46M)(259.03M)(139.39M)(14.97M)
Pre-Tax Margin—-8449.8%-434.6%-70.9%-4.0%
Income Tax Expense003.11M647K1.17M
Net Income(206.36M)(311.46M)(262.14M)(140.04M)(16.14M)
Net Margin—-8449.8%-439.8%-71.3%-4.3%
EPS (Basic)(4.17)(5.66)(3.78)(1.16)(0.13)
EPS (Diluted)(4.17)(5.66)(3.78)(1.16)(0.13)
Weighted Avg Shares49.41M55.03M69.31M120.96M127.23M
Weighted Avg Shares (Diluted)49.41M55.03M69.31M120.96M127.23M

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Intrinsic Alpha fair value

Locked

Current Price

$27.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.